Last Thursday brought the shock announcement that Novo Nordisk had made a fresh play to buy the biotech, despite Pfizer ...

A long-running confirmatory trial of two of Sarepta Therapeutics’ Duchenne muscular dystrophy drugs has missed its main goal.

Korean biosimilar specialist Celltrion has penned a deal worth more than $740 million biobucks for two preclinical autoimmune ...

Neok Bio has exited stealth with $75 million to take a pair of bispecific antibody-drug conjugates sourced from ABL Bio into ...

The precision oncology biotech is pausing work on SMARCA2 degraders and selling a licensing option to Incyte Therapeutics.

Merck & Co. began Tuesday with back-to-back deals, revealing separate agreements to pay $150 million upfront for full control of an early-phase asset and pocket $700 million to support an expansive ...

A new West Coast biotech has emerged into the busy in vivo cell therapy space, this time with the backing of Nobel Prize-winning CRISPR pioneer Jennifer Doudna, Ph.D. Azalea Therapeutics has bloomed ...

Boehringer Ingelheim’s busy year of dealmaking is showing no signs of slowing, with the German pharma now turning to established partner CDR-Life for a new trispecific autoimmune antibody. | ...

Olympus has issued updated corrective action related to the 2023 recall of more than 17,600 bronchoscopes that included flexible, fiber-optic systems and video-camera-equipped devices used to observe ...

After discussions with the FDA, Nuvation disclosed that it has “decided not to pursue a head-to-head randomized study of safusidenib against vorasidenib to support approval in non-enhancing grade 2 ...

The FDA is said to be making a U-turn on uniQure’s one-time gene therapy candidate for Huntington’s disease despite the ...

TScan Therapeutics is laying off 30% of its workforce as the T-cell receptor (TCR) therapy biotech abandons a phase 1 solid ...